A5089210450- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Medical and Health Sciences Research
- Immune Cell Function and Interaction
- Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Neuroendocrine Tumor Research Advances
- Clinical practice guidelines implementation
- Advances in Oncology and Radiotherapy
- Metastasis and carcinoma case studies
- Bladder and Urothelial Cancer Treatments
- Pulmonary Hypertension Research and Treatments
- Medical Imaging and Pathology Studies
- Sarcoma Diagnosis and Treatment
- Management of metastatic bone disease
- Medical History and Research
- Ultrasound in Clinical Applications
- Infrared Thermography in Medicine
- Radiopharmaceutical Chemistry and Applications
- Pain Management and Treatment
- Gastrointestinal Tumor Research and Treatment
Martha-Maria Hospital
2019-2024
Krankenhaus Mara
2019-2023
Institut für Zeitgeschichte München–Berlin
2019
Klinikum Ludwigshafen
1994
Odense University Hospital
1989
Characterization of host immune cell parameters before and during immunotherapy is expected to identify predictive biomarkers for clinical outcome. We prospectively monitored blood cells from 35 patients with advanced non–small lung cancer undergoing checkpoint inhibitor monotherapy. The aim was correlating better/worse Peripheral serially collected each infusion at the onset cycle 3 5 immunotherapy. A complete leukocyte count, lymphocytic subpopulations percentages both HLA-DR low monocytes...
In this exploratory prospective observational study on 40 small cell lung cancer (SCLC) patients treated with a combination of chemotherapy and immune checkpoint inhibitors, blood cells were characterized by multi-color flow cytometry at the baseline third therapy cycle. The numbers neutrophils T-, B-, NK cells, as well frequency HLA-DRlow monocytes, 6-SulfoLacNAc (slan)+ non-classical monocytes circulating dendritic (DC) subtypes determined. prognostic value parameters was evaluated...
Objectives: Small-cell lung cancer (SCLC) is a malignancy with high relapse rates and poor survival outcomes. Treatment-resistant disease occurs frequently effective salvage therapies are urgently needed. Materials Methods: We aimed to define efficacy safety of checkpoint inhibitors (CPIs) in heterogeneous population relapsed refractory SCLC patients large retrospective multicentric real-world cohort across German tertiary care centers. Results: A total 111 from 11 treatment centers were...
The aim of this study was to investigate the expression coinhibitory molecule PD-L1/CD274 in monocytes and dendritic cells (DC) blood lung cancer patients undergoing PD1 inhibitor therapy correlate data with patient’s outcome. monocytes, CD1c+ myeloid DC (mDC) CD303+ plasmacytoid (pDC) determined by flow cytometry peripheral at immunotherapy onset. predictive value PD-L1/CD274-expression patients’ survival analysis. Patients a high subpopulations rarely responded therapy. Low correlated...
Although immune checkpoint inhibitor (ICI) therapies have improved the treatment of patients with advanced non-small cell lung cancer (NSCLC), several do not achieve durable clinical responses. Biomarkers for prediction therapy responses are urgently needed. To identify blood parameters correlating patients’ survival, cells from 90 NSCLC undergoing a combination ICI and chemotherapy were prospectively monitored. At time point first third antibody administration, complete leukocyte count,...
The current S3 Lung Cancer Guidelines are edited with fundamental changes to the previous edition based on dynamic influx of information this field:The recommendations include de novo a mandatory case presentation for all patients lung cancer in multidisciplinary tumor board before initiation treatment, furthermore CT-Screening asymptomatic at risk (after federal approval), incidental nodule management , molecular testing NSCLC independent subtypes, EGFR-mutations resectable early stage...
Abstract OBJECTIVES Solitary fibrous tumours of the pleura (SFTP) are historically considered to be benign soft tissue neoplasms. However, a clinical relevant number these neoplasms have malignant histological features. The objective this study was evaluate percentage SFTP presenting unfavourable behaviour in order predict negative long-term outcome. METHODS A retrospective review 74 patients treated at 4 hospitals between 1990 and 2013 performed. median follow-up 10 years (range: 1–20...
Epididymitis is described in a man aged 33 who had been treated with the antiarrhythmic agent, amiodarone. No signs of bacterial infection or anatomical abnormalities were found. Amiodarone as cause non-infectious epididymitis has reported. This additional case stresses importance considering an adverse effect amiodarone treatment when making differential diagnosis epididymitis.
Background: Although neoadjuvant anti-PD-1 immunotherapies have shown good efficacy in non-small cell lung cancer (NSCLC) patients, there is still a lack of effective predictive markers. We aimed to develop pretreatment histologic scoring system predict the immunotherapy. Methods: One hundred forty NSCLC cases were evaluated this study. Initially, surgical specimens from 31 squamous patients treated with therapy and their eligible paired biopsies used for pathologic evaluation developing...
Small cell lung cancer (SCLC) is a rapidly growing malignancy with early distant metastases. Up to 70% will develop brain metastases, and the poor prognosis of these patients has not changed considerably. The potential checkpoint inhibitors (CPI) in treating recurrent (r/r) SCLC their effect on metastases remain unclear.In this retrospective multicenter study, we analyzed r/r receiving second or further-line CPI versus chemotherapy between 2010 2020. We applied multivariable-adjusted Cox...
An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help choice an optimal therapy duration after a primary response. In this pilot study, time courses four different cell parameters were followed 12 with advanced non-small-cell lung (NSCLC) undergoing ICI combined chemotherapy and surviving at least months. Blood was collected point first third...
Introduction: Combination immunotherapy is widely used in clinical practice as the first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, predictive factors associated with long-term response to combination have not been well investigated. Herein, we compared findings, including systemic inflammatory nutritional biomarkers, between responders and nonresponders immunotherapy. In addition, investigated Methods: This study included a total of 112 previously untreated...
Lung carcinoma is still one of the most common forms cancer in both sexes Germany and cause cancer-related death. However, we are midst a revolution treatment lung cancer. Above all, new immune target therapies as well possible combinations individual therapy components have expanded spectrum drug for recent years.Great progress has also been made other fields. Be it context early detection, where low-dose CT screening will soon be established patients at risk, or molecular diagnostics with...